1. Home
  2. CGBD vs COLL Comparison

CGBD vs COLL Comparison

Compare CGBD & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGBD
  • COLL
  • Stock Information
  • Founded
  • CGBD 2012
  • COLL 2002
  • Country
  • CGBD United States
  • COLL United States
  • Employees
  • CGBD N/A
  • COLL N/A
  • Industry
  • CGBD Finance: Consumer Services
  • COLL Biotechnology: Pharmaceutical Preparations
  • Sector
  • CGBD Finance
  • COLL Health Care
  • Exchange
  • CGBD Nasdaq
  • COLL Nasdaq
  • Market Cap
  • CGBD 1.0B
  • COLL 958.8M
  • IPO Year
  • CGBD 2017
  • COLL 2015
  • Fundamental
  • Price
  • CGBD $13.69
  • COLL $37.03
  • Analyst Decision
  • CGBD Hold
  • COLL Strong Buy
  • Analyst Count
  • CGBD 5
  • COLL 4
  • Target Price
  • CGBD $14.63
  • COLL $44.25
  • AVG Volume (30 Days)
  • CGBD 493.0K
  • COLL 380.6K
  • Earning Date
  • CGBD 08-05-2025
  • COLL 08-07-2025
  • Dividend Yield
  • CGBD 12.45%
  • COLL N/A
  • EPS Growth
  • CGBD N/A
  • COLL N/A
  • EPS
  • CGBD 1.14
  • COLL 1.06
  • Revenue
  • CGBD $234,464,000.00
  • COLL $707,007,000.00
  • Revenue This Year
  • CGBD $14.27
  • COLL $20.47
  • Revenue Next Year
  • CGBD $5.97
  • COLL $2.91
  • P/E Ratio
  • CGBD $11.94
  • COLL $35.07
  • Revenue Growth
  • CGBD N/A
  • COLL 22.61
  • 52 Week Low
  • CGBD $13.12
  • COLL $23.23
  • 52 Week High
  • CGBD $18.64
  • COLL $42.29
  • Technical
  • Relative Strength Index (RSI)
  • CGBD 44.58
  • COLL 69.53
  • Support Level
  • CGBD $13.69
  • COLL $29.70
  • Resistance Level
  • CGBD $13.85
  • COLL $38.24
  • Average True Range (ATR)
  • CGBD 0.27
  • COLL 1.23
  • MACD
  • CGBD -0.01
  • COLL 0.71
  • Stochastic Oscillator
  • CGBD 34.44
  • COLL 87.29

About CGBD Carlyle Secured Lending Inc.

Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Share on Social Networks: